Edwards Lifesciences Corp (NYSE:EW) VP Donald E. Bobo, Jr. Sells 5,369 Shares

Edwards Lifesciences Corp (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,369 shares of the business’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $234.37, for a total value of $1,258,332.53. Following the completion of the sale, the vice president now directly owns 26,082 shares of the company’s stock, valued at approximately $6,112,838.34. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

NYSE:EW traded down $0.99 during mid-day trading on Friday, reaching $234.16. 825,661 shares of the company’s stock traded hands, compared to its average volume of 1,239,245. Edwards Lifesciences Corp has a 12-month low of $139.64 and a 12-month high of $241.82. The firm has a market capitalization of $48.47 billion, a price-to-earnings ratio of 49.82, a PEG ratio of 2.81 and a beta of 0.82. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.53 and a quick ratio of 2.74. The company has a 50 day moving average price of $226.42 and a 200-day moving average price of $203.04.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $1.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.19. Edwards Lifesciences had a return on equity of 32.28% and a net margin of 18.64%. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the business earned $1.07 EPS. Edwards Lifesciences’s revenue was up 20.7% compared to the same quarter last year. As a group, analysts forecast that Edwards Lifesciences Corp will post 5.6 EPS for the current year.

Several hedge funds have recently bought and sold shares of EW. Pegasus Asset Management Inc. boosted its position in shares of Edwards Lifesciences by 0.3% in the 3rd quarter. Pegasus Asset Management Inc. now owns 14,154 shares of the medical research company’s stock worth $3,113,000 after purchasing an additional 43 shares in the last quarter. Stephens Inc. AR boosted its position in shares of Edwards Lifesciences by 0.6% in the 3rd quarter. Stephens Inc. AR now owns 7,482 shares of the medical research company’s stock worth $1,645,000 after purchasing an additional 45 shares in the last quarter. Ledyard National Bank boosted its position in shares of Edwards Lifesciences by 0.5% in the 2nd quarter. Ledyard National Bank now owns 9,178 shares of the medical research company’s stock worth $1,696,000 after purchasing an additional 50 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its position in shares of Edwards Lifesciences by 1.8% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 2,880 shares of the medical research company’s stock worth $532,000 after purchasing an additional 50 shares in the last quarter. Finally, Optimum Investment Advisors boosted its position in shares of Edwards Lifesciences by 11.1% in the 3rd quarter. Optimum Investment Advisors now owns 500 shares of the medical research company’s stock worth $110,000 after purchasing an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 81.31% of the company’s stock.

A number of equities research analysts have recently weighed in on the company. Citigroup set a $159.00 target price on Edwards Lifesciences and gave the company a “sell” rating in a research note on Friday, July 26th. BMO Capital Markets boosted their target price on Edwards Lifesciences from $204.00 to $224.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Wells Fargo & Co boosted their target price on Edwards Lifesciences from $250.00 to $262.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Barclays boosted their target price on Edwards Lifesciences from $160.00 to $175.00 and gave the company an “underweight” rating in a research note on Wednesday, July 24th. Finally, Morgan Stanley boosted their target price on Edwards Lifesciences from $228.00 to $248.00 and gave the company an “overweight” rating in a research note on Thursday, October 24th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company’s stock. Edwards Lifesciences currently has an average rating of “Buy” and a consensus target price of $237.89.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Featured Article: What Factors Can Affect Return on Equity?

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.